SPRB · Insider Trading

Spruce Biosciences, Inc. Common Stock

Every open-market purchase and sale reported by SPRB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
50
most recent
Open-Market Buys
0
code P
Sales
3
code S
Reporting Insiders
7
current holders
SPRB — Recent Form 4 Transactions (latest 2026-07-29)
FiledInsiderRole TypeSharesValue
2026-07-29 Adrian W Quartel Chief Medical Officer A +13,000 deriv. —
2026-07-09 Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER A +266 +$1.21K
2026-05-26 Michael G Grey Executive Chairman A +1,700 deriv. —
2026-05-26 Percival Barretto-Ko Director A +1,700 deriv. —
2026-05-26 Camilla V Simpson Director A +1,700 deriv. —
2026-05-26 Keli Walbert Director A +1,700 deriv. —
2026-05-26 Daniel K Spiegelman Director A +1,700 deriv. —
2026-03-09 Corwin Dale Hooks Chief Commercial Officer A +11,000 deriv. —
2026-01-21 Douglas Kirk Ways Interim Chief Medical Officer M +1,250 —
2026-01-05 Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER A +4,690 +$21.25K
2025-12-17 Samir M. Gharib PRESIDENT AND CFO MIXED +647 −$29.20K
2025-12-17 Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER MIXED +1,316 −$109.71K
2025-12-15 Keli Walbert Director A +3,400 deriv. —
2025-12-15 Percival Barretto-Ko Director MIXED — —
2025-12-15 Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER MIXED — —
2025-12-15 Michael G Grey Executive Chairman MIXED — —
2025-12-15 Daniel K Spiegelman Director MIXED — —
2025-12-15 Camilla V Simpson Director MIXED — —
2025-12-15 Samir M. Gharib PRESIDENT AND CFO MIXED — —
2025-12-12 Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER MIXED +3,524 −$230.64K
2025-12-12 Samir M. Gharib PRESIDENT AND CFO MIXED +1,550 −$75.88K
2025-10-22 Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER MIXED +3,245 −$228.02K
2025-10-22 Samir M. Gharib PRESIDENT AND CFO MIXED +1,392 −$97.93K
2025-10-15 Gregory Martinez 10%+ Owner MIXED −1 −$335
2025-10-08 Parkman Healthcare Partners LLC 10%+ Owner MIXED −1 −$335
2025-07-24 Bali Muralidhar Director A +30,000 deriv. —
2025-07-24 Camilla V Simpson Director A +30,000 deriv. —
2025-07-24 Tiba Aynechi Director A +30,000 deriv. —
2025-07-24 Kirk Ways Interim Chief Medical Officer A +30,000 deriv. —
2025-07-24 Percival Barretto-Ko Director A +30,000 deriv. —
2025-07-24 Daniel K Spiegelman Director A +30,000 deriv. —
2025-07-24 Michael G Grey Executive Chairman A +30,000 deriv. —
2024-12-20 Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER MIXED +359,870 −$96.58K
2024-12-20 Ralph William Charlton III CHIEF MEDICAL OFFICER MIXED +105,966 −$28.48K
2024-12-20 Samir M. Gharib PRESIDENT AND CFO MIXED +147,774 −$40.01K
2024-05-24 Daniel K Spiegelman Director A +30,000 deriv. —
2024-05-24 Camilla V Simpson Director A +30,000 deriv. —
2024-05-24 Michael G Grey Executive Chairman A +30,000 deriv. —
2024-05-24 Bali Muralidhar Director A +30,000 deriv. —
2024-05-24 Tiba Aynechi Director A +30,000 deriv. —
2024-05-24 Kirk Ways Director A +30,000 deriv. —
2024-05-24 Percival Barretto-Ko Director A +30,000 deriv. —
2024-03-25 Novo Holdings A/S 10%+ Owner Sell −465,021 −$350.95K
2024-03-20 Novo Holdings A/S 10%+ Owner Sell −1,794,999 −$1.36M
2024-03-18 Samir M. Gharib PRESIDENT AND CFO A +154,000 deriv. —
2024-03-18 Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER A +358,800 deriv. —
2024-03-18 Ralph William Charlton III CHIEF MEDICAL OFFICER A +106,400 deriv. —
2024-03-18 Novo Holdings A/S 10%+ Owner Sell −1,912,316 −$1.70M
2024-01-03 Ralph William Charlton III Chief Medical Officer A +9,361 +$9.15K
2024-01-03 Samir M. Gharib President & CFO A +11,255 +$11.00K
SPRB — Current Insider Holders
InsiderRole Shares HeldValue
Bali Muralidhar Director 23,900 $964.25K
Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER 19,270 $777.45K
Samir M. Gharib PRESIDENT AND CFO 8,263 $333.37K
Ralph William Charlton III CHIEF MEDICAL OFFICER 2,151 $86.78K
Douglas Kirk Ways Interim Chief Medical Officer 1,250 $50.43K
Parkman Healthcare Partners LLC 10%+ Owner 1,050 $42.36K
Gregory Martinez 10%+ Owner 1,050 $42.36K
SPRB Insider Trading FAQ
Who are the insiders at SPRB?
7 officers, directors and 10%+ beneficial owners currently report holdings in SPRB via SEC Form 4.
Are SPRB insiders buying or selling?
Across the 50 most recent Form 4 filings for SPRB, 0 were open-market purchases (code P) and 3 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is SPRB insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent SPRB filing is dated 2026-07-29.
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the SPRB quote page; the site-wide leaderboard is on the insider transactions hub.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.